Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Lyra Therapeutics (LYRA) Current Deferred Revenue (2021 - 2025)

Lyra Therapeutics (LYRA) has disclosed Current Deferred Revenue for 5 consecutive years, with $7000.0 as the latest value for Q3 2025.

  • On a quarterly basis, Current Deferred Revenue fell 98.85% to $7000.0 in Q3 2025 year-over-year; TTM through Sep 2025 was $7000.0, a 98.85% decrease, with the full-year FY2024 number at $398000.0, down 97.11% from a year prior.
  • Current Deferred Revenue was $7000.0 for Q3 2025 at Lyra Therapeutics, down from $11.9 million in the prior quarter.
  • In the past five years, Current Deferred Revenue ranged from a high of $15.7 million in Q2 2022 to a low of $7000.0 in Q3 2025.
  • A 5-year average of $8.3 million and a median of $10.9 million in 2021 define the central range for Current Deferred Revenue.
  • Biggest YoY gain for Current Deferred Revenue was 815.62% in 2025; the steepest drop was 98.85% in 2025.
  • Lyra Therapeutics' Current Deferred Revenue stood at $9.8 million in 2021, then soared by 56.83% to $15.4 million in 2022, then fell by 10.15% to $13.8 million in 2023, then crashed by 97.11% to $398000.0 in 2024, then plummeted by 98.24% to $7000.0 in 2025.
  • Per Business Quant, the three most recent readings for LYRA's Current Deferred Revenue are $7000.0 (Q3 2025), $11.9 million (Q2 2025), and $12.1 million (Q1 2025).